Roivant Sciences today announced that it has entered into a development partnership with AstraZeneca for a deprioritized investigational drug in an undisclosed indication. The drug will be developed by Roivant in a new therapeutic area that is outside of AstraZeneca's main therapy areas. Roivant has licensed global rights for its development and commercialization; deal terms include an upfront payment, development milestones, and royalties. This is the first partnership between Roivant and AstraZeneca.
"We are delighted to welcome AstraZeneca to our expanding circle of pharmaceutical partners," said Vivek Ramaswamy, Founder and CEO of Roivant Sciences. "I admire AstraZeneca's commitment to ensuring that innovative medicines reach patients, and I hope this is the first of many future collaborations."